Rapid Dose Therapeutics Corp
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark Upsdell
- Full Time Employees
- 12
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1121 Walkers Line Burlington ON Canada L7N 2G4
- IPO Date
- Dec 17, 2018
- Website
- rapid-dose.com
- Similar Companies
- Business
- Rapid Dose Therapeutics Corp. is a Canadian biotechnology company specializing in innovative proprietary drug delivery technologies designed to improve patient outcomes and quality of life. The company's main product is QuickStrip™, a thin, orally dissolvable film that can be infused with various active ingredients including nutraceuticals, pharmaceuticals, and vaccines, enabling rapid onset of the active ingredient through quick absorption into the bloodstream. The product portfolio includes pharmaceutical drug delivery solutions such as LQS™, a lidocaine-based topical anesthetic QuickStrip for dental applications, as well as nutraceutical oral dissolvable strips. Rapid Dose also offers product innovation, production, and consultation services to pharmaceutical and healthcare manufacturing industries, including nutraceutical, pharmaceutical, and cannabis sectors. The company operates primarily in Canada and has partnerships targeting markets in the United States, India, and First Nations communities in Canada, particularly through Health Canada funded harm reduction initiatives. Founded in 2014 and headquartered in Burlington, Ontario, Rapid Dose Therapeutics has undertaken several strategic initiatives within the last two years. These include extending its collaboration with an international nicotine partner to support broader commercialization of nicotine QuickStrip products, submitting its nicotine QuickStrip product for Health Canada approval, and launching a Health Canada funded SUAP harm reduction pilot project using QuickStrip technology to address opioid addiction in First Nations communities. The company completed the amalgamation of Consolidated Craft Brands in 2021, adding consumer packaged goods and health and wellness product expertise along with proprietary formulations and patent-pending technologies. It has also secured private placement financing rounds in 2024 and extended promissory notes in late 2025 to support commercial expansion and operational activities. Rapid Dose continues to expand its distribution agreements, including a three-year deal with Perennial Brands for nutraceutical oral dissolvable strips across Canada, the US, and India. These efforts underscore the company's focus on rapid product development, strategic partnerships, and expanding market reach through innovative pharma-tech solutions.
Company News
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt and Proposed Issuance of Shares as Payment of Accrued Director Fees
Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip(TM) Nicotine Patent, Advancing RDT's Global Commercialization Strategy
Rapid Dose Therapeutics (DOSE) (RDTCF) and Bodhi Health Expand Distribution and Sales of CurcuWIN(R) QuickStrip(TM) Curcumin Across Canada
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Therapeutics Extends Strategic Collaboration with Global Nicotine Leader and Initiating Saudi Arabia Commercialization
Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform
Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Completes Extension to Promissory Notes
Rapid Dose Announces Extension to Promissory Notes
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt